Gothenburg-based Anyo Labs gains ground in the AI race
In a fifty-square-metre space in Gothenburg sits a company aiming to secure its place on one of the world's hottest technological stages: AI-driven drug development. “We are driven by the technical challenge and by ensuring that we have the best possible tools,” the company’s CEO tells Life Science Sweden during our visit.
Anyo Labs’ CEO, Albin Boman, greets us and leads the way into the office. We meet at the Biotech Centre on Medicinareberget in Gothenburg, and the company’s connection to the city is clear. In the neighbouring space on the same floor, Sahlgrenska Science Park has set up its premises.
All five co-founders of Anyo Labs met within Gothenburg’s academic environment. It all began when two researchers in computational chemistry at the University of Gothenburg, Leif Eriksson and Sayyed Jalil Mahdizadeh, recognised the limitations of existing methods and saw the need for safer and faster ways to develop drug candidates.